Even better deliverability for the outstanding Orsiro DES1
Find out more Orsiro® Mission DESThe Orsiro DES Family has an extensive clinical program with
> 100’000 patients enrolled or planned2
Juan F. Iglesias, MD, Geneva, Switzerland
Juan F. Iglesias, MD, Geneva, Switzerland
Proven superiority*,3
STEMI = ST-Elevation Myocardial Infarction
*Target Lesion Failure at 5-year follow-up Orsiro DES: 7.7% Xience DES: 11.1% BIOSTEMI with historical information RR, 0.70; 95% BCI, 0.51-0.95, Bayesian posterior probability, 0.988 Difference: -31%. **Orsiro Mission DES is not indicated for one month of dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients. Please refer to the IFU for indications and post-procedure antiplatelet therapy recommendations. §Always refer to your local IFU
1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. BIOTRONIK data on file. Status February 2023; 3. Iglesias, JF. Long-Term Outcomes with Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction: 5-Year Follow-up of the BIOSTEMI Randomized Trial, Presented at: TCT 2023; October 25, 2023; San Francisco, USA.
Clinical data collected with either Orsiro DES or Orsiro Mission DES device within the Orsiro family clinical program.
Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies. All other trademarks are the property of their respective owners.
© 2024 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.
